Protara Therapeutics Inc (NAS:TARA)
$ 5.51 0.01 (0.18%) Market Cap: 189.10 Mil Enterprise Value: 112.00 Mil PE Ratio: 0 PB Ratio: 1.39 GF Score: 40/100

Protara Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) - On-Demand Transcript

May 24, 2022 / 11:00AM GMT
Release Date Price: $3.14
Thomas Yip
H.C. Wainwright & Co., LLC - Analyst

Hello, everyone. Welcome to the 2022 HC Wainwright Global Investment Conference. This is Thomas Yip from H.C. Wainwright. For our next presentation, we have Mr. Jesse Shefferman, CEO of Protara Therapeutics, a clinical-stage company, developing treatments for oncology and other rare diseases.

Jesse, very happy to have you with us today. Please go ahead.

Jesse Shefferman
Protara Therapeutics, Inc. - Co-Founder, Director & CEO

Thanks, Thomas, and thank you to the broader Wainwright team for having us on. I'm going to start with just a quick scan through, an overview of Protara, and then we'll jump right into where we will spend the majority of our time, which is on TARA-002, our lead candidate for bladder cancer and lymphatic malformations.

So who is Protara? We, as you mentioned, are a oncology and rare disease focused company. We're based in New York City. And our lead program, TARA-002, is a bacterial immunopotentiator, based on an originator therapy used for oncology for over 40

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot